

7th DIA Cell and Gene Therapy Products Symposium in Japan

“Ten Years Progress of Cell and Gene Therapy Products – Leap forward with our initial passion”

December 15-16, 2022

Hybrid | KFC Hall <http://www.tokyo-kfc.co.jp/access> & Virtual

Since the legislative Regenerative Medicine Promotion Act in 2013, clinical development of many regenerative medical products for intractable diseases has accelerated and many such products are currently being used in clinical practice. This annual symposium has continuously discussed “practical aspects” such as the industrialization, practical use, and eventual mastery of regenerative medical products in clinical practice.

The year 2022 marks the “ten years since the legislation” milestone. This year’s symposium, subtitled “Ten Years Progress of Cell and Gene Therapy Products – Leap forward with our initial passion,” is intended to recall and reignite our original passion to “ensure that we deliver new solutions to patients” at the time of the law was issued, our aspirations to realize it, to look back on the progress of product development, and to prepare for a further leap forward.

In a special lecture, Dr. Daisaku Sato (Ministry of Health, Labour and Welfare), whose work was dedicated to enactment of the law, will discuss the philosophy and thought at the time it was enacted. In Session 1, key panelists from industry, government, and academia will review their accumulated achievements to discuss future development. Other sessions will discuss a viral safety assurance strategy based on revision of ICH-Q5A; a manufacturing control strategy utilizing the international standard; and introduce the latest nonclinical research topics based on different ways of thinking between cell and gene therapy products in nonclinical studies. Another session will feature presentations from physician who are heavy users of regenerative medical products.

Keynote lectures from thought leaders Dr. Yoshiki Sawa (Osaka Police Hospital) and Dr. Keiya Ozawa (Jichi Medical University) will review their initial passion, encourage passion from the audience, and set expectations for further advances in cell therapy and gene therapy products. In addition, Dr. Jacqueline Barry will share her valuable knowledge and experience in the educational lecture Strategy from searching new seeds to development.

Like previous years, our 7th DIA Cell and Gene Therapy Products Symposium in Japan will share issues among industry, government, and academia, and provide a forum for constructive discussions and solutions. This year presents a wider range of topics than ever across **two days you don’t want to miss!!**

We plan to hold a hybrid meeting. Networking at the venue will resume. We look forward to this opportunity to expand our network with many people. In addition to a service for downloading presentation materials (as PDF files), we also plan to offer a service for distributing videotapes of each session and keynote speech for a limited time after the symposium.* We are confident that these will allow you to make full use of the symposium contents in accordance with your needs, and look forward to welcoming as many participants as possible this year.

*Please note that there may be restrictions on recording and sharing materials based on the content and nature of each session or lecture.

Expected contributors:

- Individuals involved in the development of regenerative medical products in pharmaceutical or medical device companies and related industries.
- Individuals involved in the development of regenerative medical products in venture companies or academic institutions.
- Individuals involved in regulatory submissions work for regenerative and related medical products.

Please Click [here](#) for COVID-19 Measures

Exhibit Opportunities Available

For information, contact DIA Japan
Nihonbashi Life Science Building 6F,
2-3-11 Nihonbashi-honcho, Chuo-ku, Tokyo 103-0023 Japan
Tel: +81.3.6214.0574 | Fax: +81.3.3278.1313
Email: Japan@DIAglobal.org



DIA Japan
Nihonbashi Life Science Building 6F,
2-3-11 Nihonbashi-honcho, Chuo-ku, Tokyo 103-0023 Japan
Tel: +81.3.6214.0574 Fax: +81.3.3278.1313 Email: Japan@DIAglobal.org

Drug Information Association

Global Center: Washington, DC | Americas | Europe, Middle East & Africa | China | Japan | India



PROGRAM CHAIR

- **Yoji Sato, PhD**
National Institute of Health Sciences (NIHS)
- **Masafumi Onodera, MD, PhD**
National Center for Child Health and Development

PROGRAM VICE-CHAIR

- **Hiromi Okabe, PhD**
Novartis Pharma K.K.
- **Yasuko Terao, PhD**
Janssen Pharmaceutical K.K.

PROGRAM COMMITTEE

- **Teruyo Arato, PhD**
Hokkaido University Hospital
- **Satoru Hayata, MS**
Sobi Japan
- **Ryutarō Hirasawa, PhD**
Daiichi Sankyo Co., Ltd.
- **Akiko Ikeda**
Janssen Pharmaceutical K.K.
- **Ikuo Kawauchi**
FUJIFILM Holdings Corporation
- **Sumimasa Nagai, MD, PhD**
Kyoto University
- **Shinichi Noda, PhD**
Pharmaceuticals and Medical Devices Agency (PMDA)
- **Kiyoshi Okada, MD, PhD**
Osaka University
- **Hiroyuki Suda, MSc**
KORTUC Inc.
- **Yoshie Tsurumaki**
Novartis Pharma K.K.

AD-HOC MEMBER

- **Keiji Miyamoto,**
Daiichi Sankyo Co., Ltd.

OPERATION TEAM

- **Akiko Nishioka**
Novartis Pharma K.K.

Simultaneous Translation Available

WHO SHOULD ATTEND?

- Cell and gene therapy product development professionals in pharmaceutical companies, medical devices companies, venture companies, regulatory agencies, or academia.

- DIA volunteers, members, and staff provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications, and educational materials, throughout the year, all around the world.

DIAglobal.org

10:00-10:15 WELCOME AND OPENING REMARKS**Hajime Saijo, PhD**

Senior Vice President & Managing Director, DIA Japan

Yoji Sato, PhDProgram Chair
Head, Division of Cell-Based Therapeutic Products, National Institute of Health Sciences(NIHS)**10:15-10:45 SPECIAL LECTURE****SESSION CHAIR****Yoji Sato, PhD**

Head, Division of Cell-Based Therapeutic Products, National Institute of Health Sciences(NIHS)

TBD**Daisaku Sato, PhD**Director, Compliance and Narcotics Division.
Ministry of Health, Labour and Welfare (MHLW)**10:45-11:00 SHORT BREAK****11:00-12:50 SESSION 1****Looking Back on the Past Nine Years for a Further Leap Forward****SESSION CO-CHAIRS****Kiyoshi Okada, MD, PhD**

Specially Appointed Associate Professor, Graduate School of Medicine, Osaka University

Sumimasa Nagai, MD, PhDInstitute for Advancement of Clinical and Translational Science (iACT)
Kyoto University Hospital

Year 2022 is the 10th year from the revision of the Safety assurance for regenerative medicine Law and the PMD Law in 2013. Over the past 9 years, the development of regenerative medical products has progressed, and new products are gradually coming to the market. Four products have been approved under the conditional approval system. In their development, various challenges, focusing on how development of these products is different from biological drug and medical device development, have been identified.

In this session, key panelists from industry, government, and academia will review these revisions and share their concerns about prior development, review and approval, related decisions made, and their prospects and hopes for the future.

TBD**Yoji Sato, PhD**

Head, Division of Cell-Based Therapeutic Products, National Institute of Health Sciences(NIHS)

TBD**Masafumi Onodera, MD, PhD**

Director, Gene & Cell Therapy Promotion Center, NCCHD

TBD**Kenichiro Hata, MD, PhD**

President & CEO, Japan Tissue Engineering Co., Ltd.

Panel Discussion**All Session Speaker and****Yoshiki Sawa, MD, PhD**

Hospital Director, Osaka Police Hospital

Yoshiaki Maruyama, PhD

Review Director, Pharmaceutical and Medical Devices Agency (PMDA)

12:50-14:00 LUNCH BREAK**14:00-15:00 KEYNOTE ADDRESS 1****SESSION CHAIR****Yoji Sato, PhD**

Head, Division of Cell-Based Therapeutic Products, National Institute of Health Sciences(NIHS)

TBD**Yoshiki Sawa, MD, PhD**

Hospital Director, Osaka Police Hospital

15:00-15:20 COFFEE BREAK**15:20-17:00 SESSION 2****Revision of ICH Q5A and Upcoming Challenges for Virus Safety Management of Gene and Cell Therapy Products****SESSION CO-CHAIRS****Yoji Sato, PhD**

Head, Division of Cell-Based Therapeutic Products, National Institute of Health Sciences (NIHS)

Ryutarō Hirasawa, PhD

CMC Regulatory Affairs, Manager, Daiichi Sankyo Co., Ltd.

Virus safety management is one of the essential issues in assuring the quality (quality assurance) of gene and cell therapy products. This annual symposium has previously discussed topics regarding the revision of the ICH Q5A guideline and virus safety assessment with new technologies, including upcoming challenges. This year, we will discuss an advanced approach for virus safety management in the context of the upcoming release of the ICH Q5A (R2) draft and review the basic concept of this guideline.

This session will feature experts with crosscutting experiences across different types of products, provide opportunity to discuss regulatory and technological challenges for future virus safety management.

Overview of ICH-Q5A(R2) and basic approach to ensuring the virus safety of gene and cell therapy products**Akira Sakurai, PhD**

Specialist, Pharmaceuticals and Medical Devices Agency (PMDA)

Global trend in the substitution of in vivo testing/ antibody production testing by molecular methods**Alison Armstrong, PhD**

Senior Director, Global Head of the Technical and Scientific Solutions, Merck

Practical application of virus filtration for gene therapy products**Tomoko Hongo-Hirasaki, PhD**

Lead expert, Asahi Kasei Medical Co., Ltd.

Panel Discussion**All Session Speakers and****Yuko Kato-Mori, PhD**

President & Director of Virus Study Department, ViSpot Inc.

17:00-17:10 SHORT BREAK**17:10-17:50 EDUCATIONAL LECTURE****SESSION CHAIR****Masafumi Onodera, MD, PhD**

Director, Gene & Cell Therapy Promotion Center, NCCHD

TBD**Jacqueline Barry, PhD**

Cell and Gene Therapy Catapult

17:50-18:00 SHORT BREAK**18:00-19:00 NETWORKING**

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that the DIA.

Speakers and agenda are subject to change without notice.
Recording of any DIA tutorial/workshop/meeting information in any type of media, is prohibited without prior written consent from DIA.

9:00-10:50 SESSION 3**Manufacturing Management Strategy Utilizing International Standards****SESSION CO-CHAIRS****Sumimasa Nagai, MD, PhD**Institute for Advancement of Clinical and Translational Science(iACT)
Kyoto University Hospital**Ikuo Kawauchi, MS**International Standards Promotion Office, Intellectual Property Div.
FUJIFILM Holdings Corporation

International standards in the fields of regenerative medicine are developed and published mainly by ISO/TC 276 (Biotechnology). These standards can be classified into three categories: products and services of supporting industries, manufacturing, and analytical methods.

After a brief explanation of standards, this session will discuss the characteristics of standards related to supporting industries such as reagents and media, manufacturing equipment, and transportation; development of a "cell processing management standard" plan for consistent manufacturing; and overview the "testing and characterization of cellular therapeutic products," "cell counting," and "cell viability" for analytical methods standards. Panel discussion will examine how utilization of these standards, including expected effects and measures to facilitate utilization, contributes to manufacturing management.

International Standards Related to Products and Services of Supporting industries**Ikuo Kawauchi, MS**International Standards Promotion Office, Intellectual Property Div.
FUJIFILM Holdings Corporation**Standardization in Cell Processing Management****Ryui Kato, PhD**

Associate Professor, Tokai National Higher Education and Research System, Nagoya University

Testing and Characterization of Cellular Therapeutic Products**Yuzuru Ito, PhD**

Professor, Faculty of Life and Environmental sciences, University of Tsukuba

Trends in international Standards for Cell Analysis including Cell Counting and Cell Viability**Masakazu Kadowaki, PhD**

Director, Business Incubation, Sysmex Corporation

Panel Discussion**All Session Speakers****Shinichi Noda**Office of Cellular and Tissue-based Products, Deputy Review Director,
Pharmaceuticals and Medical Devices Agency(PMDA)**10:50-11:10 COFFEE BREAK****11:10-12:50 SESSION 4****Tips and Pitfalls for Preparing Cell and Gene Therapy Product Non-Clinical Studies****SESSION CO-CHAIRS****Teruyo Arato, PhD**

Professor, Hokkaido University Hospital

Hiroyuki Suda

VP, Clinical Strategy, KORTUC Inc.

Cell therapy and gene therapy products are treated as the same category in the regenerative medical products regulations in Japan. However, different approaches are required in designing non-clinical studies, since certain characteristics of cell therapy and gene therapy products are quite different.

This session will broadly cover non-clinical studies on regenerative medical products by examining the differences in regulatory requirements between these two modalities, with experts in each area sharing their approaches to current issues and hot topics.

TBD**Teruhide Yamaguchi, PhD**

Professor, Kanazawa-Institute of Technology

TBD**Akihiko Taguchi, MD, PhD**

Department of Regenerative Medicine Research, Institute of Biomedical

Research and Innovation

TBD**Yoza Nakazawa, MD, PhD**Professor, Department of pediatrics, Shinshu University School of
Medicine**TBD****Takefumi Gemba, PhD**Executive Director, Clinical & Regulatory Strategy,
Labcorp Development Japan K. K.**14:55-15:10 LUNCH BREAK****15:10-15:50 KEYNOTE ADDRESS 2****SESSION CHAIR****Masafumi Onodera, MD, PhD**

Director, Gene & Cell Therapy Promotion Center, NCCHD

TBD**Keiya Ozawa, MD, PhD**

Professor Emeritus and Visiting Professor, Jichi Medical University

15:50-17:30 SESSION 5**How to Deliver Cellular and Gene Therapy Products: Feedback from Medical Institutions****SESSION CO-CHAIRS****Masafumi Onodera, MD, PhD**

Director, Gene & Cell Therapy Promotion Center, NCCHD

Hideki Mochizuki, MD

Graduate School of Medicine, Osaka University

As of July 2022, 16 cellular and tissue-based products have been launched across various modalities such as tissue-engineered products, cell-based products, ex vivo cell therapy products, and gene therapy products. But much effort is required to use these products in medical institutions, including preparation for and introduction to actual operation, actual operation, improving operations required to use and administer these products, and contrivances to improve their therapeutic effects.

In this session, physicians with real-world experience with using commercial cellular and tissue-based products will speak about their previous experiences, current situation, and proposals for future improvement. Panel discussion will examine requests to companies and regulatory authorities for clinical use.

TBD**Takahiro Ueda, MD**Professor, Altitude Emergency and critical care medical center, Tottori
University Hospital**TBD****Yuki Kato, MD**

Chief, Sports Medicine Center, Kameda Medical Center

TBD**Kentaro Fukushima, MD**Senior Lecturer, Department of Hematology and Oncology, Graduate
School of Medicine, Osaka University**Lights and Shadows in CAR-T Cell Therapy - Expectation and Exhaustion of the Clinical Team****Yasuyuki Arai, MD, PhD**Senior Lecturer, Center for Research and Application of Cellular
Therapy, Kyoto University Hospital**Using Zolgensma in the Real World****Yuko Shimizu-Motohashi, MD**Department of Child Neurology, National Center of Neurology and
Psychiatry**Panel Discussion****All Session Speakers****17:30-17:45 CLOSING REMARKS****Masafumi Onodera, MD, PhD**Program Chair
Director, Gene & Cell Therapy Promotion Center, NCCHD

REGISTRATION FORM: Register online or forward to
DIA Japan, Nihonbashi Life Science Building 6F, 2-3-11 Nihonbashi-
honcho, Chuo-ku, Tokyo 103-0023 Japan
tel +81-3-6214-0574 • fax +81-3-3278-1313

7th DIA Cell Therapy and Gene Therapy Products Symposium in Japan

Event #22313 • December 15-16, 2022 | Hybrid | KFC Hall (Virtual)

DIA will send participants a confirmation letter within 10 business days after receipt of their registration.

Registration Fees If DIA cannot verify your membership, you will be charged the nonmember fee. Registration fee includes refreshment breaks and reception (if applicable), and will be accepted by mail, fax, or online.

Join DIA now to save on future meetings and to enjoy the benefits of membership for a full year: www.DIAglobal.org/Membership

- I **DO** want to be a DIA member
 I **DO NOT** want to be a DIA member

		10% CONSUMPTION TAX INCLUDED		
MEMBER *	Industry	Early Bird (Until Nov. 24, 2022)	¥55,440	<input type="checkbox"/>
		On of After Nov.25, 2022	¥63,360	<input type="checkbox"/>
	Government, Non Profit, Academia, Medicals	Early Bird (Until Nov. 24, 2022)	¥29,700	<input type="checkbox"/>
		On of After Nov.25, 2022	¥33,000	<input type="checkbox"/>
NONMEMBER	Industry	¥86,460	<input type="checkbox"/>	
	Government	¥56,100	<input type="checkbox"/>	
	Non Profit, Academia, Medicals	¥48,840	<input type="checkbox"/>	
MEMBERSHIP * * *	Membership	¥27,346	<input type="checkbox"/>	
	2-Year Membership	¥49,223	<input type="checkbox"/>	
	Academia Membership (Academia, Medicals)**	¥20,205	<input type="checkbox"/>	
	2-year Academia Membership (Academia, Medicals)**	¥36,369	<input type="checkbox"/>	

Consumption tax will not be added to participants from outside Japan
 * Including members of Forum for Innovative Regenerative Medicine (FIRM).

** To register for Academia Membership, please send this form to DIA Japan office by fax or e-mail.

***Revised from July 1, 2022

Please check the applicable category:

- Academia Government Industry Medicals
 CSO (Contract research/service organization) Student (Call for registration information)

Last Name _____

First Name _____ M.I. _____

Degrees _____ Dr. Mr. Ms.

Job Title _____

Company _____

Address (As required for postal delivery to your location) _____

City _____ State _____ Zip/Postal _____ Country _____

email **Required for confirmation** _____

Phone Number **Required** _____ Fax Number _____

DIA Terms and Conditions

CANCELLATION POLICY: On or before November 17, 2022

Administrative fee that will be withheld from refund amount:

Member or Nonmember = ¥20,000

Government/Academia/Nonprofit

(Member or Nonmember) = ¥10,000

Cancellations must be in writing and be received by the cancellation date above. Registrants who do not cancel by that date and do not attend will be responsible for the full registration fee paid.

Registrants are responsible for cancelling their own hotel and airline reservations. You may transfer your registration to a colleague at any time but **membership is not transferable**. Please notify DIA of any such substitutions as soon as possible. Substitute registrants will be responsible for nonmember fee, if applicable.

EVENT STREAM AND RECORDING

If you attend a DIA event, we make video and audio recordings of events (both face to face and online) that may include your participation in the event, including your image, questions and comments. To view our full photography and video recording policy, click [here](https://www.DIAglobal.org/general/photography-policy).
 (https://www.DIAglobal.org/general/photography-policy)

PRIVACY STATEMENT

The personal information you request will be used for the purpose of sending conference information from DIA. In addition, in the web conference, we will use the information with the name of the company or organization and the name of everyone who participates, and it will be used for networking with participants, related parties, exhibiting companies for the period and about two weeks after the event. .. By submitting this application form, it is interpreted that you have consented to the above handling of personal information, but if you do not agree, please contact DIA Japan.

By signing below I confirm that I agree with DIA's Terms and Conditions of booking. These are available from the office or online by clicking [here](https://www.diaglobal.org/General/Terms-and-Conditions?productIDs=9276679).
 (https://www.diaglobal.org/General/Terms-and-Conditions?productIDs=9276679)

Signature _____

Date _____

PAYMENT OPTIONS

Register online at www.DIAglobal.org or check payment method.

BANK TRANSFER:

You will receive an invoice with bank information detail by email after registration completion.

All local and overseas charges incurred for the bank transfer must be borne by payer.

CREDIT CARD (VISA, MASTERCARD OR JCB ONLY)

VISA **MC** **JCB** Exp. (mm/yy) _____

Card No. _____

Cardholder Name _____

Signature _____

CONTACT INFORMATION

Contact the DIA Japan office in Tokyo for further information.

tel: +81.3.6214.0574 | fax: +81.3.3278.1313

email: Japan@DIAglobal.org

www.diajapan.org

